Pfizer COVID shot safely bolsters antibodies in younger kids
Pfizer Inc. and partner BioNTech SE said their COVID-19 vaccine was safe and produced strong antibody responses in children ages 5 to 11 in a large-scale trial.
Pfizer Inc. and partner BioNTech SE said their COVID-19 vaccine was safe and produced strong antibody responses in children ages 5 to 11 in a large-scale trial.